Lubiprostone for the Treatment of Chronic Idiopathic Constipation
Status:
Completed
Trial end date:
2017-01-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of oral administration of
lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic
constipation (CIC) compared with placebo.